Background Combining Trastuzumab with chemotherapy for HER2-positive gastric cancer shows treatment promise but may … raise costs. We aimed to evaluate the cost-effectiveness of combining Trastuzumab with chemotherapy for HER2-positive … trastuzumab plus chemotherapy versus chemotherapy alone. The PSM framework included three distinct health states: progression …

Objectives: Trastuzumab deruxtecan (T-DXd) was recently recommended by the Committee for Medicinal Products for Human … prior anti-HER2-based regimen. In our study, we evaluated the cost-effectiveness of T-DXd compared with ado-trastuzumab …